WASHINGTON — The U.S. On Friday, U.S. health regulators approved a new medicine for women suffering from hot flashes triggered by menopause.
The Food and Drug Administration approved Astellas Pharma’s once-daily medication to treat moderate-to-severe symptoms such as perspiration, flushing, and chills.
Veozah, an Astellas medication, takes a novel strategy by targeting brain connections that assist control body temperature. According to the FDA, the medicine will provide “an additional safe and effective treatment option for women,” according to a statement.
According to the FDA, hot flashes affect more than 80% of women during menopause, when the body gradually generates fewer quantities of reproductive hormones between the ages of 45 and 55.
According to the FDA, hot flashes affect more than 80% of women during menopause.
The most typical treatment includes hormone tablets that increase estrogen and progestin levels. However, the treatment is unsuitable for many women, particularly those with a history of stroke, blood clots, heart attack, or other medical issues. Large studies have revealed that hormones can raise the likelihood of such issues recurring. However, the risks vary depending on a variety of individual circumstances.
The new pill does not contain any hormones. It is labeled with an FDA warning concerning potential liver harm. According to the FDA label, women must be checked for liver damage or infection before receiving a prescription and have a blood test every three months for nine months to monitor for safety issues.
According to Astellas, a one-month medicine supply will cost $550. That is the cost before insurance and other discounts, often negotiated by insurers and pharmacy benefit managers.
SOURCE – (AP)
